

## IN THIS ISSUE

A Side-by-Side Comparison of Results in Eyebrow Restoration Using Single-Hair Grafts vs Two- and Three-Hair Grafts

## The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata

Sukhmani Pannu, MD | New York, New York, USA; Nathalie Ly, BS | Minneapolis, Minnesota, USA; Zehara Abidi, MS | New York, New York, USA; Sophia Fruechte, BS, Ronda Farah, MD | Minneapolis, Minnesota, USA; Suleima Arruda, MD, Neil Sadick, MD | New York, New York, USA; Maria Hordinsky, MD | Minneapolis, Minnesota, USA | [drsukhmanipannu@gmail.com](mailto:drsukhmanipannu@gmail.com)

### ABSTRACT

Alopecia areata (AA), with a disease incidence of 2% in the USA, is the most common immune-mediated cause of hair loss in the world. There were no FDA approved treatments for AA in the past. All treatment modalities used alone or in combination with each other, were prescribed off label. The JAK inhibitor baricitinib was approved by the FDA in June 2022. While it's a significant leap forward, we are still missing the safety profile data in multiple areas. Topical JAK inhibitors are being tested along with sublingual options including tofacitinib, ruxolitinib, and ritlecitinib. In this review, we discuss the JAK inhibitor baricitinib in detail, along with its dosing regimen, challenges presented in the clinic, missing data, and what the future may hold.

**Keywords:** alopecia areata, baricitinib, FDA approved, JAK inhibitors

*This article is open access and may not be copied, distributed, or modified without written permission from the International Society of Hair Restoration Surgery.*


### INTRODUCTION

Alopecia areata (AA) is the most common immune mediated cause of hair loss in the world.<sup>1,2</sup> The disease incidence in the USA and United Kingdom is approximately 2%.<sup>3</sup> AA affects both children and adults and does not show a preference for gender, skin type, hair type, or hair color.<sup>2</sup> AA is characterized by a circular well-circumscribed area of hair loss, typically on the scalp or face, but it can affect any hair-bearing region.<sup>1,2</sup> It can range in severity from patchy, diffuse involvement to more severe forms involving the entire scalp or all body hair. AA can be a self-limiting condition that often results in spontaneous regrowth, but as an autoimmune disease, disease extent and activity can vary and patients can experience recurrent episodes of patchy or extensive hair loss.<sup>1,3,4</sup> While the disease mechanisms driving AA have not been fully determined, it is clear that genetic predisposition and autoimmunity are key contributors together with likely environmental factors.<sup>3</sup> Genetic epidemiology has demonstrated an increased risk of AA in first degree relatives, with the incidence being between 10% and 50%.<sup>1,3,5</sup> This genetic predisposition has been linked to the major histocompatibility complex (MHC) gene and more specifically to the human leukocyte antigen (HLA) class II genes.<sup>1,3,5</sup> Many single nucleotide polymorphisms (SNPs) associated with AA led to the identification of candidate susceptibility genes through genome-wide association studies (GWASs).<sup>1,3,5</sup> Previous studies showed that AA largely involves attack of the hair follicle bulb region by autoreactive CD8+ T-cells, which comprise the characteristic "swarm of bees" around the hair follicle bulb in AA. These autoreactive T-cells are initially activated by numerous cytokine pathways that utilize the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling.<sup>1-4</sup> Treatment of AA has been challenging in the past due to an inadequate understanding of the pathogenesis of the disease.<sup>6</sup>

### Past and Current Treatments for AA

Current treatment strategies for patients with AA differ based on several factors including disease severity, affected area(s), and patient age. Broadly, these can be categorized into three groups: topical, intra-lesional, and systemic therapies.

Traditional first-line therapies for patients with limited AA include topical (TCs) and intralesional corticosteroids (ICs). For both children and adults, use of higher potency TCs is preferred as they have



## TABLE OF CONTENTS

- 153 The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
- 155 President's Message
- 156 Guest Co-Editors' Messages
- 157 Notes from the Editor Emeritus: Dr. Andreas Finner
- 167 A Side-by-Side Comparison of Results in Eyebrow Restoration Using Single-Hair Grafts vs Two- and Three-Hair Grafts
- 173 Literature Review
- 174 The Notable Articles Project
- 179 ABHRS President's Corner
- 180 Message from the ISHRS 2022 World Congress Program Chair
- 182 Meeting Reviews: 13th Annual Hair Transplant 360 Cadaver Workshop & 8th Congress of the Brazilian Association of Hair Restoration Surgery
- 188 Classified Ads
- 189 Calendar of Events

## HAIR TRANSPLANT FORUM INTERNATIONAL

is published bi-monthly by the  
*International Society of Hair Restoration Surgery*

First-class postage paid Milwaukee, WI and  
additional mailing offices.

POSTMASTER Send address changes to:

*Hair Transplant Forum International*  
*International Society of Hair Restoration Surgery*  
1932 S. Halsted St., Suite 413  
Chicago, IL 60608 USA  
Telephone 1-630-262-5399  
U.S. Domestic Toll Free 1-800-444-2737  
Fax 1-630-262-1520

President	Nilofer Farjo, MBChB, FISHRS <a href="mailto:president@ishrs.org">president@ishrs.org</a>
Executive Director	Victoria Ceh, MPA <a href="mailto:vceh@ishrs.org">vceh@ishrs.org</a>
Guest Editors	David S. Josephitis, DO, FISHRS Venkataram N. Mysore, MD, FISHRS <a href="mailto:forumeditors@ishrs.org">forumeditors@ishrs.org</a>
Managing Editor & Advertising Sales	Cheryl Duckler <a href="mailto:cduckler@ishrs.org">cduckler@ishrs.org</a>

## COLUMNISTS

ABHRS President's Corner	Timothy Carman, MD, FISHRS
Controversies	Russell G. Knudsen, MBBS, FISHRS
Hair's the Question	Sara M. Wasserbauer, MD, FISHRS
Hear from the Assistants	Marwan Noureldin, MSc
How I Do It	Timothy Carman, MD, FISHRS
Literature Review	Aditya K. Gupta, MD, PhD, FISHRS Nicole E. Rogers, MD, FISHRS
Meeting Review	Rachael Kay, MBChB
World Congress Program Chair	Sara M. Wasserbauer, MD, FISHRS

The views expressed herein are those of the individual author and are not necessarily those of the International Society of Hair Restoration Surgery (ISHRS), its officers, directors, or staff. Information included herein is not medical advice and is not intended to replace the considered judgment of a practitioner with respect to particular patients, procedures, or practices. All authors have been asked to disclose any and all interests they have in an instrument, pharmaceutical, cosmeceutical, or similar device referenced in, or otherwise potentially impacted by, an article. ISHRS makes no attempt to validate the sufficiency of such disclosures and makes no warranty, guarantee, or other representation, express or implied, with respect to the accuracy or sufficiency of any information provided. To the extent permissible under applicable laws, ISHRS specifically disclaims responsibility for any injury and/or damage to persons or property as a result of an author's statements or materials or the use or operation of any ideas, instructions, procedures, products, methods, or dosages contained herein. Moreover, the publication of an advertisement does not constitute on the part of

ISHRS a guaranty or endorsement of the quality or value of the advertised product or service or of any of the representations or claims made by the advertiser.

Hair Transplant Forum International is a privately published newsletter of the International Society of Hair Restoration Surgery. Its contents are solely the opinions of the authors and are not formally "peer reviewed" before publication. To facilitate the free exchange of information, a less stringent standard is employed to evaluate the scientific accuracy of the letters and articles published in the Forum. The standard of proof required for letters and articles is not to be compared with that of formal medical journals. The newsletter was designed to be and continues to be a printed forum where specialists and beginners in hair restoration techniques can exchange thoughts, experiences, opinions, and pilot studies on all matters relating to hair restoration. The contents of this publication are not to be quoted without the above disclaimer.

The material published in the Forum is copyrighted and may not be utilized in any form without the express written consent of the Editor(s).

Copyright © 2022 by the  
*International Society of Hair Restoration Surgery*,  
1932 S. Halsted St., Suite 413  
Chicago, IL 60608 USA

Printed in the USA.



Official Publication of the  
*International Society of Hair Restoration Surgery*